Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings
December 09, 2024 16:05 ET
|
OncoCyte Corporation
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings – January 13-16, 2025, San Francisco, CA
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study
December 04, 2024 16:15 ET
|
OncoCyte Corporation
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study
Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms
December 02, 2024 16:05 ET
|
OncoCyte Corporation
Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient population Study shows that monitoring with Oncocyte’s assay significantly reduces time to...
Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025
November 12, 2024 16:05 ET
|
OncoCyte Corporation
Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025
Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12
November 06, 2024 16:45 ET
|
OncoCyte Corporation
Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12
Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles
October 16, 2024 16:15 ET
|
OncoCyte Corporation
Oncocyte Announces Participation in the LD Micro Main Event XVII
Conference in Los Angeles
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial
October 08, 2024 08:30 ET
|
OncoCyte Corporation
Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO...
Oncocyte Signs Leading Transplant Centers in US and Germany
October 02, 2024 18:41 ET
|
OncoCyte Corporation
GraftAssure™ research assay adopted by two research hospitals that are top-five-in-country by organ transplant volumeCompany clears first stage gate in clinical product development process and has...
Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
October 02, 2024 18:35 ET
|
OncoCyte Corporation
IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that it has entered into a...
Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study
August 12, 2024 16:10 ET
|
OncoCyte Corporation
Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study